Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | EIF4E | P06730 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.37 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4503148 | 0.86 | HTT (0.36) | GPR119EIF4EMKNK1MKNK2CYP2C9 | |
| SCHEMBL12170572 | 0.86 | EIF4E (0.46) | GPR119ROCK1EIF4EMKNK1MKNK2 | |
| SCHEMBL4494380 | 0.80 | ALDH1A1 (0.39) | GPR119EIF4EMKNK1MKNK2HTT | |
| SCHEMBL375962 | 0.79 | GPR119 (0.61) | GPR119CYP2C9 | |
| SCHEMBL4492509 | 0.79 | HTT (0.40) | GPR119CYP2C9HTT | |
| SCHEMBL4491806 | 0.77 | GPR119 (0.37) | GPR119HTTEGFR | |
| SCHEMBL4487002 | 0.72 | GPR119 (0.53) | GPR119CYP2C9 | |
| SCHEMBL4497686 | 0.69 | HTT (0.37) | GPR119ROCK1EIF4EMKNK1MKNK2 | |
| SCHEMBL30964509 | 0.69 | EGFR (0.52) | ROCK1EIF4EMKNK1MKNK2CYP2C9 | |
| SCHEMBL4502152 | 0.69 | P2RX7 (0.38) | HTTEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222261-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2012-07-17 | — | — | US | disclosed |
| US-20090318477-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318477-A1 | CHEMICAL COMPOUNDS | GPR119, GOT2, SLC5A2 | GPR119 1/4885ROCK1 3485/4885EIF4E 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.